[Comparative pharmacologic economic efficacy of alpha-adrenoblockers produced by different manufacturing firms for the management of chronic prostatitis].
The article is devoted to the study of pharmacoeconomic efficiency of use of alpha-blockers for treating chronic prostatitis. Setegis 2 mg, cardura 2 mg, magurol 2 mg were employed in the study. Expediency is proved of employment of alpha-blockers in a complex treatment of chronic prostatitis. No clinically significant advantages have been revealed in a comparative evaluation of drugs produced by different firms of manufacturers in treatment of chronic prostatitis. Revealed in the study was economic expediency of making use of the EGIS firm alpha-blocker (Setegis 2 mg), which fact is accounted for by a lower comparative cost of the drug in the retail market of Ukraine and by its identical, in fact, clinical effectiveness.
Martynenko
A V
AV
D000317:Adrenergic alpha-Antagonists / Q000191:economics* / Q000627:therapeutic use*; D002908:Chronic Disease; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D004364:Pharmaceutical Preparations / Q000191:economics*; D011472:Prostatitis / Q000188:drug therapy*
D000317:Adrenergic alpha-Antagonists; D004364:Pharmaceutical Preparations
Sravitel'naia farmakoékonomicheskaia éffektivnost' alpha-adrenoblokatorov razlichnykh firm proizvoditeleĭ pri lechenii khronicheskogo prostatita.